Sofosbuvir–velpatasvir in children 3–17 years old with hepatitis C virus infection
Journal of Pediatric Gastroenterology and Nutrition · 2024-06 · 78 (6) · 1342-1354
DOI: 10.1002/jpn3.12045 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Pediatric Gastroenterology and Nutrition, online erschienen am 21.04.2024. Verfasst von Maureen M Jonas und 22 weiteren Autor:innen. Beteiligte Einrichtung: Boston Children's Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Sofosbuvir, Heterocyclic Compounds, 4 or More Rings, Carbamates, Antiviral Agents. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Gilead Sciences Inc..
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
The safety and efficacy of sofosbuvir–velpatasvir in children aged 3–17 years with chronic hepatitis C virus (HCV) infection of any genotype were evaluated.
Methods
In this Phase 2, multicenter, open‐label study, patients received once daily for 12 weeks either sofosbuvir–velpatasvir 400/100 mg tablet (12–17 years), 200/50 mg low dose tablet or oral granules (3–11 years and ≥17 kg), or 150/37.5 mg oral granules (3–5 years and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Boston Children's Hospital, Boston, Massachusetts, USA.
- Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA.
- Division of Pediatric Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, University of California San Francisco, Benioff Children's Hospital, San Francisco, California, USA.
- Children's Hospital Los Angeles, Los Angeles, California, USA.
- Università di Bologna, Bologna, Italy.
- University of Pennsylvania and The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Förderung
- Gilead Sciences Inc.
Zitieren
APA
Jonas, M. M., Romero, R., Rosenthal, P., Lin, C. H., Verucchi, G., Wen, J., Balistreri, W. F., Whitworth, S., Bansal, S., Leung, D. H., Narkewicz, M. R., Gonzalez-Peralta, R. P., Mangia, A., Karnsakul, W., Rao, G. S., Shao, J., de Jong, J., Parhy, B., Osinusi, A., …, & Schwarz, K. B. (2024). Sofosbuvir–velpatasvir in children 3–17 years old with hepatitis C virus infection. Journal of Pediatric Gastroenterology and Nutrition, 78(6), 1342-1354. https://doi.org/10.1002/jpn3.12045
Vancouver
Jonas MM, Romero R, Rosenthal P, Lin CH, Verucchi G, Wen J, et al. Sofosbuvir–velpatasvir in children 3–17 years old with hepatitis C virus infection. Journal of Pediatric Gastroenterology and Nutrition. 2024;78(6):1342-1354. doi:10.1002/jpn3.12045
BibTeX
@article{Jonas2024,
author = {Jonas, Maureen M and Romero, Rene and Rosenthal, Philip and Lin, Chuan-Hao and Verucchi, Gabriella and Wen, Jessica and Balistreri, William F and Whitworth, Suzanne and Bansal, Sanjay and Leung, Daniel H and Narkewicz, Michael R and Gonzalez-Peralta, Regino P and Mangia, Alessandra and Karnsakul, Wikrom and Rao, Girish S and Shao, Jiang and de Jong, Jan and Parhy, Bandita and Osinusi, Anu and Kersey, Kathryn and Murray, Karen F and Sokal, Etienne M and Schwarz, Kathleen B},
title = {Sofosbuvir–velpatasvir in children 3–17 years old with hepatitis C virus infection},
journal = {Journal of Pediatric Gastroenterology and Nutrition},
year = {2024},
volume = {78},
number = {6},
pages = {1342--1354},
doi = {10.1002/jpn3.12045}
}
EUVIMED